AIMS: Fibrate treatment induces adverse changes in biliary-lipid and bile-acid composition. Since the molecular mechanisms underlying these changes are still unclear, we have investigated the effect of fibrate treatment on key factors involved in bile-acid synthesis, biliary-lipid secretion and cholesterol metabolism in gallstone patients. METHODS:Patients with uncomplicated gallstones and a serum level of low-density lipoprotein (LDL) cholesterol >130 mg/dl were randomly assigned to open-label treatment with bezafibrate, fenofibrate, gemfibrozil, or placebo for 8 weeks before elective cholecystectomy. A liver specimen was obtained at operation, and the mRNA relative levels for cholesterol 7alpha-hydroxylase (CYP7A1), hepatocyte nuclear factor-4 (HNF-4), ATP-binding cassette transporters MDR3, ABCG5, and ABCG8, human homologue scavenger receptor BI, sterol response element binding protein-2 (SREBP-2), 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase and LDL receptor were determined by means of reverse-transcriptase polymerase chain reaction. RESULTS:Bezafibrate, fenofibrate and gemfibrozil significantly reduced CYP7A1 mRNA levels. The three fibrates tested raised the mRNA levels of ABCG5 and SREBP-2, but only bezafibrate induced significant changes. Although MDR-3 mRNA levels were slightly increased by the three fibrates, no significant differences were obtained. CONCLUSIONS: These results show for the first time that fibrate administration to humans downregulates CYP7A1. Although ABCG5 and SREBP-2mRNA levels were slightly increased by all treatment groups, only bezafibrate induced significant changes.
RCT Entities:
AIMS: Fibrate treatment induces adverse changes in biliary-lipid and bile-acid composition. Since the molecular mechanisms underlying these changes are still unclear, we have investigated the effect of fibrate treatment on key factors involved in bile-acid synthesis, biliary-lipid secretion and cholesterol metabolism in gallstonepatients. METHODS:Patients with uncomplicated gallstones and a serum level of low-density lipoprotein (LDL) cholesterol >130 mg/dl were randomly assigned to open-label treatment with bezafibrate, fenofibrate, gemfibrozil, or placebo for 8 weeks before elective cholecystectomy. A liver specimen was obtained at operation, and the mRNA relative levels for cholesterol 7alpha-hydroxylase (CYP7A1), hepatocyte nuclear factor-4 (HNF-4), ATP-binding cassette transporters MDR3, ABCG5, and ABCG8, human homologue scavenger receptor BI, sterol response element binding protein-2 (SREBP-2), 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase and LDL receptor were determined by means of reverse-transcriptase polymerase chain reaction. RESULTS:Bezafibrate, fenofibrate and gemfibrozil significantly reduced CYP7A1 mRNA levels. The three fibrates tested raised the mRNA levels of ABCG5 and SREBP-2, but only bezafibrate induced significant changes. Although MDR-3 mRNA levels were slightly increased by the three fibrates, no significant differences were obtained. CONCLUSIONS: These results show for the first time that fibrate administration to humans downregulates CYP7A1. Although ABCG5 and SREBP-2 mRNA levels were slightly increased by all treatment groups, only bezafibrate induced significant changes.
Authors: G Chinetti; F G Gbaguidi; S Griglio; Z Mallat; M Antonucci; P Poulain; J Chapman; J C Fruchart; A Tedgui; J Najib-Fruchart; B Staels Journal: Circulation Date: 2000-05-23 Impact factor: 29.690
Authors: Liqing Yu; Jia Li-Hawkins; Robert E Hammer; Knut E Berge; Jay D Horton; Jonathan C Cohen; Helen H Hobbs Journal: J Clin Invest Date: 2002-09 Impact factor: 14.808
Authors: Nisanne S Ghonem; Meenakshisundaram Ananthanarayanan; Carol J Soroka; James L Boyer Journal: Hepatology Date: 2014-01-27 Impact factor: 17.425
Authors: Tomoyuki Nishimoto; Michael A Pellizzon; Masakazu Aihara; Ioannis M Stylianou; Jeffery T Billheimer; George Rothblat; Daniel J Rader Journal: Arterioscler Thromb Vasc Biol Date: 2009-07-02 Impact factor: 8.311